Sol-Gel Technologies’ work to expand the treatment options for patients with the skin condition rosacea has paid off, with the FDA approving a product based on its microencapsulation technology.
Sol-Gel Technologies is now rated 'Hold' due to reliance on a single late-stage asset and limited pipeline depth. Read the ...
NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical ...
Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...
Just because a business does not make any money, does not mean that the stock will go down. For example, Sol-Gel Technologies (NASDAQ:SLGL) shareholders have done very well over the last year, with ...
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse ...
NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback